EXACT Sciences Corporation (NASDAQ:EXAS) most recently reported quarterly actual earnings per share of $-0.46 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $-0.55. The difference between the estimate and the actual EPS was $0.09 creating a surprise factor of 16.36%. Currently, the company has an impact score of 86. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0.456. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.

In taking a look at where the stock might be headed, analysts have a consensus price target of $15.777 on the shares. The most bullish brokerage firm has a $26 target, while the most bearish sees the stock headed towards $8. This is according to the 9 estimates taken into consideration by Zacks Research.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 9 recommendations taking into account in order to arrive at this number. Of the 9, 5 have a Strong Buy rating and 0 are rating it a Buy.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company’s Cologuard test is a non-invasive, stool-based DNA (sDNA) screening test designed to detect deoxyribonucleic acid (DNA) markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The target sensitivity rate of its Cologuard test for cancer is equal to or greater than 85% at a specificity of 90%.

EXACT Sciences Corporation - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.